Laidlaw Wealth Management’s Novo Nordisk NVO Stock Holding History

Laidlaw Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,624	Closed	-$209K	–	368
2023 Q1	$209K	Buy	+2,624	New	+$186K	0.04%	329

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laidlaw Wealth Management's NVO Position: Q2 2023 in Review

Laidlaw Wealth Management sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 2,624 shares — an estimated $209K sold.

Laidlaw Wealth Management first reported a position in NVO in Q1 2023 and held it in 1 quarter. The position peaked at $209K in Q1 2023. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

Laidlaw Wealth Management reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
Laidlaw Wealth Management sold 2,624 Novo Nordisk shares in Q2 2023, an estimated $209K.
Laidlaw Wealth Management first reported a position in Novo Nordisk in Q1 2023 and held it in 1 quarter.
Laidlaw Wealth Management's Novo Nordisk position peaked at $209K in Q1 2023.
1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Laidlaw Wealth Management's 13F filing for Q2 2023, filed 14 Aug 2023.